ReviewNature reviews. Chemistry2026
Precision chemical engineering of dendrimers for nucleic acid delivery.
Review in Nature reviews. Chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Nucleic acid therapeutics, including oligonucleotides, messenger RNA and DNA, are promising drug modalities for treating various diseases. However, despite their increasing impact on medicine, their precise and efficient delivery remains a considerable challenge. Dendrimers, recognized by their uniquely branched architecture and precise structures in concert with cooperative multivalency, are a platform for targeted and precise delivery of nucleic acid therapeutics. Here we review state-of-the-art engineering of dendrimers pertaining to nucleic acid delivery, highlighting progress made in their design and functional mechanization for delivering different types of nucleic acids for therapeutic applications. We also discuss challenges including manufacturing, safety and regulatory issues associated with their clinical applications. Finally, we conclude by offering our perspective on dendrimer engineering that are expected to overcome current obstacles for advancing nucleic acid therapeutics development.
Indexed as
Identifiers
42458028What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.